Time to sputum culture conversion, treatment outcomes, and associated factors among rifampicin-resistant or multidrug-resistant tuberculosis patients in the Sidama region, Ethiopia: A retrospective follow-up study

埃塞俄比亚锡达马地区利福平耐药或多重耐药结核病患者痰培养转阴时间、治疗结果及相关因素:一项回顾性随访研究

阅读:1

Abstract

BACKGROUND: Time to sputum culture conversion is critical for follow-up treatment effectiveness in multidrug-resistant tuberculosis patients. However, the evidence regarding time to culture conversion, treatment outcomes, and the associated factors was sparse and inconsistent. OBJECTIVE: This study aimed to determine the time to culture conversion, treatment outcomes, and associated factors among rifampicin-resistant and multidrug-resistant tuberculosis cases in the Sidama region from April 1 to December 31, 2024. METHODS: We conducted a retrospective follow-up study of 346 patients who enrolled between January 2013 and June 2024. We collected data from patients' medical records using a standardized form, entered the data, and analyzed it using Stata 16.1 software. We performed the analysis using the Kaplan-Meier model for time to culture conversion, Weibull distribution gamma frailty, and logistic regression models to assess factors associated with time to culture conversion and treatment outcomes, respectively. We considered an adjusted hazard or odds ratio with a 95% CI and a p-value < 0.05 to determine significance. RESULTS: Among the participants, 302 (87.3%) achieved culture conversion in a median time of 76 days (95% CI: 71-79 days). Patients with a history of previous loss to follow-up experienced an approximately fivefold delay in culture conversion (AHR = 0.2; 95% CI: 0.1-0.6; p = 0.001), while relapse cases had a twofold delay (AHR = 0.5; 95% CI: 0.2-0.9; p = 0.02) compared with new patients. The treatment success rate was 234/346 (67.6%). Female patients had higher odds of achieving a favorable treatment outcome (AOR = 1.8; 95% CI: 1.0-3.3; p = 0.04), whereas patients who experienced culture reversion had significantly lower odds of a favorable outcome (AOR = 0.05; 95% CI: 0-0.4; p = 0.001). CONCLUSIONS: The majority of patients experienced culture conversion within three months. However, patients with a history of loss to follow-up and relapse experienced delayed culture conversion. These findings highlight the urgent need to improve patient adherence.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。